Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

High incidence of cetuximab-related infusion reactions in head and neck cancer pts (real life data)

Date

09 Oct 2016

Session

Poster display

Presenters

Virginia Coloma

Citation

Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376

Authors

V. Coloma, M. Annereau, N. Lezghed, C. Even, L. Mayache-Badis, M. Iacob, C. Leibu, M. Matias, P. Bravo, C. Ferte

Author affiliations

  • Gustave Roussy, Université Paris-saclay, Villejuif, F-94805, France, Institut Gustave Roussy, 94805 - Villejuif/FR
More

Resources

Background

Cetuximab is crucial in the management of squamous cell carcinoma of the head and neck (SCCHN) patients. Grade 3-4 infusion reactions (IRs) occur in 2% of colorectal cancer (ASPECCT study, ∼1000 pts). Despite the 2.7% IR rate in the EXTREME trial (NEJM 2008), higher rates were reported in small series of SCCHN (6-10%). There is an urgent need to better appraise the natural history and the predictive factors for IRs in HNSCC pts exposed to Cetuximab.

Methods

The medical records from all consecutive SCCHN patients (n = 451) treated by cetuximab at Gustave Roussy (Cancer Campus Grand Paris) from January 2013 to December 2015 were reviewed. IR severity was defined as per the NCI-CTCAE v4.0. The impact of potential risk factors was analyzed (history of allergy, biological and clinicopathological variables).

Results

All patients analyzed received pre-medication including corticosteroids and antihistamines. Out of 441 patients, 34 patients (7.5%) presented grade 3-4 IR, nearly all of them requiring intensive care unit referral. Most of the IRs occurred during the first cycle (range: 1-3). The occurrence of grade 3-4 IR was associated with prior allergy history (P 

Conclusions

In real life, grade 3-4 IR consecutive to cetuximab appears far more common (7.5%) than reported in prospective trials. This is the largest series of patients ever focusing on the risk of IR induced by cetuximab in SCCHN pts. History of prior allergy is a strong predictor of IR and could be used to better allocate treatment and supervise pts. Further prospective data are however required to confirm this.

Clinical trial identification

Gustave Roussy, Université Paris-Saclay, Villejuif, F-94805, France

Legal entity responsible for the study

Gustave Roussy, Université Paris-Saclay, Villejuif, France

Funding

Gustave Roussy, Université Paris-Saclay, Villejuif, France

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings